Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways

Shock

Volumn 34, Issue 1, 2010, Pages 10-16

  Kreth, Simone ^a   Ledderose, Carola ^b   Luchting, Benjamin ^a   Weis, Florian ^a   Thiel, Manfred ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

A2A receptor; cAMP; PMN leukocytes; sepsis; T cells

Indexed keywords

ADENOSINE; ADENOSINE A2A RECEPTOR; CD3 ANTIBODY; GAMMA INTERFERON; HYDROGEN PEROXIDE; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOCLONAL ANTIBODY CD28; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IMMUNOMODULATION; NEUTROPHIL; T LYMPHOCYTE;

ADENOSINE; ANTIGENS, CD28; ANTIGENS, CD3; CELLS, CULTURED; HUMANS; HYDROGEN PEROXIDE; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; NEUTROPHILS; NF-KAPPA B; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953879755     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181cdc3e2     Document Type: Article

References (48)

1. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 348:138-150, 2003.
2. Shimaoka M, Park EJ: Advances in understanding sepsis. Eur J Anaesthesiol Suppl 42:146-153, 2008.
3. Rittirsch D, Flierl MA, Ward PA: Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8:776-787, 2008.
4. Marshall JC: Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2:391-405, 2003.
5. Russell JA: Management of sepsis. N Engl J Med 355:1699-1713, 2006.
6. Parrish WR, Gallowitsch-Puerta M, Czura CJ, Tracey KJ: Experimental therapeutic strategies for severe sepsis: mediators and mechanisms. Ann N Y Acad Sci 1144:210-236, 2008.
7. Ulloa L, Tracey KJ: The Bcytokine profile[: a code for sepsis. Trends Mol Med 11:56-63, 2005.
8. Deree J, Lall R, Melbostad H, Grant M, Hoyt DB, Coimbra R: Neutrophil de-granulation and the effects of phosphodiesterase inhibition. J Surg Res 133: 22-28, 2006.
9. + monocyte-derived dendritic cells. J Immunother 30:89-95, 2007.
10. Zhang M, Xu YJ, Saini HK, Turan B, Liu PP, Dhalla NS: Pentoxifylline attenuates cardiac dysfunction and reduces TNF-alpha level in ischemic-reperfused heart. Am J Physiol Heart Circ Physiol 289:H832-H839, 2005.
11. Wang W, Zolty E, Falk S, Basava V, Reznikov L, Schrier R: Pentoxifylline protects against endotoxin-induced acute renal failure in mice. Am J Physiol Renal Physiol 291:F1090-F1095, 2006.
12. D'Hellencourt CL, Diaw L, Cornillet P, Guenounou M: Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline. Int J Immunopharmacol 18:739-748, 1996.
13. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrick J: Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 155:1230-1236, 1988.
14. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med 30:1-6, 2002.
15. Staubach KH, Schroder J, Stuber F, Gehrke K, Traumann E, Zabel P: Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch Surg 133:94-100, 1998.
16. Zimmerman JJ: Appraising the potential of pentoxifylline in septic premies. Crit Care Med 27:695-697, 1999.
17. Coimbra R, Melbostad H, Loomis W, Tobar M, Hoyt DB: Phosphodiesterase inhibition decreases nuclear factor-kappaB activation and shifts the cytokine response toward anti-inflammatory activity in acute endotoxemia. J Trauma 59:575-582, 2005.
18. Coimbra R, Melbostad H, Loomis W, Porcides RD, Wolf P, Tobar M: LPS-induced acute lung injury is attenuated by phosphodiesterase inhibition: effects on proinflammatory mediators, metalloproteinases, NF-kappaB, and ICAM-1 expression. J Trauma 60:115-125, 2006.
19. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M: Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 22:657-682, 2004.
20. Kreth S, Kaufmann I, Ledderose C, Luchting B, Thiel M: Reduced ligand affinity leads to an impaired function of the adenosine A2A receptor of human granulocytes in sepsis. J Cell Mol Med 13:985-994, 2009.
21. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45, 2001.
22. Andersen CL, Jensen JL, Orntoft TF: Normalization of real-time quantitative reverse transcriptionYPCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64:5245-5250, 2004.
23. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J: International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552, 2001.
24. Sliwa K, Woodiwiss A, Kone VN, Candy G, Badenhorst D, Norton G: Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 109:750-755, 2004.
25. Shaw SM, Shah MK, Williams SG, Fildes JE: Immunological mechanisms of pentoxifylline in chronic heart failure. Eur J Heart Fail 11:113-118, 2009.
26. Sliwa K, Woodiwiss A, Candy G, Badenhorst D, Libhaber C, Norton G: Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idio-pathic dilated cardiomyopathy. Am J Cardiol 90:1118-1122, 2002.
27. Zeni F, Pain P, Vindimian M, Gay JP, Gery P, Bertrand M: Effects of pent-oxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. Crit Care Med 24:207-214, 1996.
28. Ridings PC, Windsor AC, Sugerman HJ, Kennedy E, Sholley MM, Blocher CR: Beneficial cardiopulmonary effects of pentoxifylline in experimental sepsis are lost once septic shock is established. Arch Surg 129:1144-1152, 1994.
29. Lombardi MS, Kavelaars A, Heijnen CJ: Role and modulation of G proteinY coupled receptor signaling in inflammatory processes. Crit Rev Immunol 22: 141-163, 2002.
30. Kehrl JH: G-proteinYcoupled receptor signaling, RGS proteins, and lymphocyte function. Crit Rev Immunol 24:409-423, 2004.
31. Thiel M, Caldwell CC, Sitkovsky MV: The critical role of adenosine A2A receptors in downregulation of inflammation and immunity in the pathogene-sis of infectious diseases. Microbes Infect 5:515-526, 2003.
32. Ohta A, Sitkovsky M: Role of G-proteinYcoupled adenosine receptors in down-regulation of inflammation and protection from tissue damage. Nature 414: 916-920, 2001.
33. Lappas CM, Sullivan GW, Linden J: Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin Investig Drugs 14:797-806, 2005.
34. Moore CC, Martin EN, Lee GH, Obrig T, Linden J, Scheld WM: An A2A adenosine receptor agonist, ATL313, reduces inflammation and improves survival in murine sepsis models. BMC Infect Dis 8:141, 2008.
35. Kreth S, Ledderose C, Kaufmann I, Groeger G, Thiel M: Differential expression of 5'-UTR splice variants of the adenosine A2A receptor gene in human gran-ulocytes: identification, characterization, and functional impact on activation. FASEB J 22:3276-3286, 2008.
36. Hasko G, Linden J, Cronstein B, Pacher P: Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7:759-770, 2008.
37. Rowe J, Finlay-Jones JJ, Nicholas TE, Bowden J, Morton S, Hart PH: Inability of histamine to regulate TNF-alpha production by human alveolar macro-phages. Am J Respir Cell Mol Biol 17:218-226, 1997.
38. Dent G, Giembycz MA, Rabe KF, Wolf B, Barnes PJ, Magnussen H: Theophylline suppresses human alveolar macrophage respiratory burst through phosphodiesterase inhibition. Am J Respir Cell Mol Biol 10:565-572, 1994.
39. Sands WA, Palmer TM: Regulating gene transcription in response to cyclic AMP elevation. Cell Signal 20:460-466, 2008.
40. Kamthong PJ, Wu M: Inhibitor of nuclear factor-kappaB induction by cAMP antagonizes interleukin-1-induced human macrophage-colony-stimulating-factor expression. Biochem J 356:525-530, 2001.
41. Minguet S, Huber M, Rosenkranz L, Schamel WW, Reth M, Brummer T: Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immunoreceptors. Eur J Immunol 35:31-41, 2005.
42. Koga K, Takaesu G, Yoshida R, Nakaya M, Kobayashi T, Kinjyo I: Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. Immunity 30:372-383, 2009.
43. Wang W, Tam WF, Hughes CC, Rath S, Sen R: c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. Immunity 6: 165-174, 1997.
44. Di Virgilio F, Chiozzi P, Ferrari D, Falzoni S, Sanz JM, Morelli A: Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 97:587-600, 2001.
45. Pozo D: VIP-and PACAP-mediated immunomodulation as prospective therapeutic tools. Trends Mol Med 9:211-217, 2003.
46. Samten B, Townsend JC, Weis SE, Bhoumik A, Klucar P, Shams H: CREB, ATF, and AP-1 transcription factors regulate IFN-gamma secretion by human T cells in response to mycobacterial antigen. J Immunol 181:2056-2064, 2008.
47. Mayr B, Montminy M: Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2:599-609, 2001.
48. Ramakers BP, Pickkers P, Deussen A, Rongen GA, van den Broek P, van der Hoeven JG, Smits P, Riksen NP: Measurement of the endogenous adenosine concentration in humans in vivo: methodological considerations. Curr Drug Metab 9:679-685, 2008.